42.68 +0.28 (0.66%)
After hours: 6:47PM EST
|Bid||0.00 x 800|
|Ask||42.68 x 1000|
|Day's Range||42.04 - 43.50|
|52 Week Range||33.20 - 46.47|
|Beta (3Y Monthly)||0.75|
|PE Ratio (TTM)||10.71|
|Earnings Date||Jan 28, 2019 - Feb 1, 2019|
|Forward Dividend & Yield||1.44 (3.29%)|
|1y Target Est||44.78|
Over the past month, shares of the Boeing Company (BA) have been battered significantly as a result of multiple headwinds. Boeing holds the eighth-place spot among the 16 Dow 30 stocks that have posted YTD gains. Boeing was the Dow’s top performer for most of 2017, earning its investors 88% in the year.
On December 14, Pfizer (PFE) announced a dividend of $0.36 for the first quarter of fiscal 2019. Pfizer announced that the dividend would be payable to shareholders on record at the close of the market on February 1. Pfizer’s dividend of $0.36 is 6% higher than the previous dividend of $0.34.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 29, 2019. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.
Health care stocks are among a handful of sectors bucking the broader market downturn in 2018. Biotechs, though down for the year, have suffered less damage than other stocks. One factor that worked in ...
Lilly (LLY) inks a deal with privately held Hydra Biosciences to add the latter's pre-clinical pain candidate to its portfolio.
Kineta Immuno-Oncology to receive $15 million upfront and will be eligible to receive up to $505 million in potential research, development and sales milestone payments Research collaboration focused on ...
Of the 14 analysts covering Ionis Pharmaceuticals (IONS), five have given it “buy” or higher ratings, seven have given it “holds,” and two have given it “sells.”
In the most recent quarter, Ionis Pharmaceuticals’ (IONS) selling, general, and administrative expenses rose YoY (year-over-year) to $68.71 million from $26.79 million. Meanwhile, its R&D (research and development) expenses rose YoY to $95.25 million from $80.21 million due to higher drug development costs.
Ionis Pharmaceuticals’ (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake. In its Core Ionis segment, the company is using its antisense technology to develop a pipeline of best-in-class drugs.
shares traded lower Friday even as the pharmaceutical group boosted it latest quarterly dividend and said it would buyback another $10 million in company stock in what may be the last corporate act of outgoing CEO Ian Read. Pfizer said it had approved a 36 cents per share dividend, a 6% increase from the same period last year which will be paid on March 1 and authorized a new, $10 billion share repurchase plan, adding to an existing program of around $4.9 billion, which will be phased in over an unspecified period of time. The first quarter dividend is Pfizer's 321st consecutive shareholder payout by the New York based pharmaceutical group.
A panel of European Medicines Agency (EMA) on Friday recommended approval for Pfizer Inc's Zirabev, a cheaper version to Roche Holding AG's leading cancer drug Avastin. Pfizer's Zirabev is the second cancer biosimilar from the drugmaker to receive a positive opinion from the European advisory panel this year. Roche has been facing declining sales for its three leading cancer drugs - Avastin, Herceptin, Rituxan - due to severe competition from low-cost versions called biosimilars.
The board of directors of Pfizer Inc. today declared a 36-cent first-quarter 2019 dividend on the company’s common stock, payable March 1, 2019, to shareholders of record at the close of business on February 1, 2019. Pfizer increased the dividend by approximately 6 percent, to 36 cents from 34 cents per share. The first-quarter 2019 cash dividend will be the 321st consecutive quarterly dividend paid by Pfizer.
ZIRABEV™ , a potential biosimilar to Avastin®* , is Pfizer’s second therapeutic oncology biosimilar to receive a positive CHMP opinion in Europe in 2018
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.
Merck and Co said on Friday it will buy privately held French company Antelliq Group, which makes digital identification products for livestock, for about 2.1 billion euros ($2.37 billion) to bolster its fast-growing animal health business. The move affirms the drugmaker's commitment to the business, which Wall Street analysts have long seen value in separating just as rival drugmakers Eli Lilly and Co and Pfizer Inc did. Pfizer's Zoetis raised $2.2 billion in a 2013 IPO, while Elanco, the former animal health business at Lilly, raised $1.51 billion from an IPO in September.
Pfizer Inc. (PFE) announced today the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older. “While the full extent of Prevenar 13 protection of adults is still being realized, we anticipate our 20vPnC vaccine candidate will be the next important step to help protect adults from a substantial invasive pneumococcal disease and pneumonia burden, including disease caused by serotypes not yet covered by any available conjugate vaccine,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer.
NEW YORK, NY / ACCESSWIRE / December 14, 2018 / U.S. markets finished modestly higher on Thursday as investors continue to worry about trade tensions between the U.S. and China. The Dow Jones Industrial ...
In 2018 and 2019, Biogen (BIIB) is expected to generate revenues of $13.31 billion and $13.66 billion, respectively, compared to $12.27 billion in 2017.